SHPH Key Statistics, Chart & Performance
The current stock price of SHPH is 1.791 USD. In the past month the price decreased by -9.8%. In the past year, price decreased by -89.94%.
SHPH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SHPH. When comparing the yearly performance of all stocks, SHPH is a bad performer in the overall market: 96.35% of all stocks are doing better.
SHPH Financial Highlights
Over the last trailing twelve months SHPH reported a non-GAAP Earnings per Share(EPS) of -25.87. The EPS increased by 9.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -302.2% | ||
| ROE | -767.95% | ||
| Debt/Equity | 0.3 |
SHPH Forecast & Estimates
SHPH Ownership
SHPH Latest News, Press Relases and Analysis
SHPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.39 | 398.827B | ||
| AMGN | AMGEN INC | 15.55 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.13 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.6 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 11.47 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.35 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SHPH
Company Profile
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
Company Info
SHUTTLE PHARMACEUTICALS HOLD
401 Professional Drive, Suite 260
Gaithersburg MARYLAND US
Employees: 9
Phone: 12404034212
SHUTTLE PHARMACEUTICALS HOLD / SHPH FAQ
What does SHUTTLE PHARMACEUTICALS HOLD do?
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
What is the current price of SHPH stock?
The current stock price of SHPH is 1.791 USD. The price decreased by -2.66% in the last trading session.
What is the dividend status of SHUTTLE PHARMACEUTICALS HOLD?
SHPH does not pay a dividend.
What is the ChartMill rating of SHUTTLE PHARMACEUTICALS HOLD stock?
SHPH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for SHUTTLE PHARMACEUTICALS HOLD?
SHUTTLE PHARMACEUTICALS HOLD (SHPH) operates in the Health Care sector and the Biotechnology industry.